Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14528798 | 1.00 | ALOX5 (0.51) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL28905936 | 0.84 | ALOX5 (0.58) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL28905939 | 0.84 | ALOX5 (0.58) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL28905959 | 0.84 | ALOX5 (0.58) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL14033888 | 0.83 | ALOX5 (0.49) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9902506 | 0.83 | ALOX5 (0.46) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL28791917 | 0.82 | ALOX5 (0.49) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL9902253 | 0.80 | ALOX5 (0.46) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL13704231 | 0.80 | ALOX5 (0.46) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11520602 | 0.77 | ALOX5 (0.51) | ALOX5CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9186651-B2 | Metal organic framework modified materials, methods of making and methods of using same | CORNELL UNIVERSITY (US) | 2015-11-17 | — | — | US | disclosed |
| WO-2012027538-A2 | METAL ORGANIC FRAMEWORK MODIFIED MATERIALS, METHODS OF MAKING AND METHODS OF USING SAME | CORNELL UNIVERSITY CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COMMERCIALIZATION ("CCTEC") (US) | 2012-03-01 | — | — | WO | disclosed |
| US-7872011-B2 | Inhibition of phosphoinositide 3-kinase β | ASTRAZENECA AB (SE) | 2011-01-18 | — | — | US | disclosed |
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | KINACIA PTY. LTD. (AU) | 2008-12-25 | — | — | US | disclosed |
| US-7405211-B2 | Using 2-morpholinyl-4H-pyrido(1,2-a)pyrimidin-4-one; enzyme inhibitors; antithrombotic agents ; restenosis; atherosclerosis; antihistamines; chronic obsessive pulminary disease; autoimmune diseases; anticancer agents; antiinflammatory agents | ASTRAZENECA AB (SE) | 2008-07-29 | — | — | US | disclosed |
| EP-1857443-A2 | Therapeutic morpholino-substituted compounds | AstraZeneca AB (SE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1257537-B1 | THERAPEUTIC MORPHOLINO-SUBSTITUTED COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319021-A1 | Inhibition Of Phosphoinositide 3-Kinase Beta | PI4KB, PI4KA, PI4K2B | ALOX5 2961/4885CHRNB2 4368/4885CHRNB4 4210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.